Balderton Capital Raises New $600m Early-stage Fund to Back Europe’s Next Wave of Breakout Tech
17.11.2021 11:00:00 EET | Business Wire | Press release
Balderton Capital has raised its second fund of 2021 – a $600m fund focused on early-stage companies – to support its mission to be the leading provider of venture capital and founder support to European startups with global ambitions.
With close to 300 investments made since the firm was founded 21 years ago, Balderton has extensive experience backing exceptional founders from seed to growth stage, Europe-wide. Since the start of the year, Balderton has invested in 20 new startups in sectors ranging from reproductive health and instant commerce to data labelling and gaming.
The firm has also seen 13 portfolio companies achieve unicorn status this year, underlining the fund’s long track record of picking category leaders early. Companies where Balderton invested at Seed or Series A, include Aircall, Beauty Pie, ComplyAdvantage, Contentful, Depop, Dream Games, GoCardless, Infarm, Labster, Revolut, Vestiaire Collective and Zego.
“Balderton Capital is a very different firm than it was 12 months ago. We have not only launched two new funds, but have grown and strengthened our team. We have entered a new era in which we will be able to operate at a different pace and with a broader view of when we can support founders. Our transition from Europe’s leading Series A investor to a multi-stage fund gives us more firepower and flexibility and helps us to uncover more hidden gems among Europe’s startups.” Bernard Liautaud, Managing Partner at Balderton Capital, said.
Balderton’s portfolio companies have collectively raised more than $6bn in follow-on funding this year to date, almost double the $3.1bn raised in the entirety of 2020. Four portfolio companies – Darktrace, Flywire, SOPHiA Genetics and Truecaller – have also gone public in landmark European IPOs and the firm has seen 10 exits, including Peakon’s sale to Workday, Nutmeg’s sale to JPMorgan Chase and Depop’s sale to Etsy.
“The launch of Fund VIII marks 21 years of seed and Series A investing at Balderton. In that time we have had the huge privilege to work with many irrepressible founders with outsized ambitions and we hope to do so once again.” said General Partner Suranga Chandratillake. “While our job may not have changed, Europe has - we are excited for the thriving ecosystem we find around us with more talent, more capital and more ambition than at any time in our history.”
Rana Yared, General Partner, added: “We pull out all the stops to help our founders be successful operationally, and by investing at both early stage and further down the line, we are also able to offer the long-term partnership and capital they need to help them achieve their ambitions. We are delighted to be able to support a new generation of entrepreneurs through this fund.”
Committed to European tech ambition
With Europe on track to raise a record $70bn of venture capital investment by the end of the year, more than twice the total for 2020, Balderton Capital has doubled down on its commitment to building the next generation of global tech companies from the region.
The firm is one of only a handful of genuinely pan-European investors with partners in key hubs across the region. The firm has raised four funds totalling close to $2bn since 2018 and has active investments in more than 100 companies, employing more than 26,000 people in 50 countries around the world.
The new fund will be sector agnostic and managed by Balderton’s investment team of 25 working across Europe. The equal partnership will work together to share experience and insights to the benefit of the entire portfolio.
Founder-focused
Balderton’s portfolio companies benefit from its Build with Balderton platform of talent, marketing, finance and legal services. The Platform is wholly focused on giving founding teams the help they need to scale, including access to operational and functional services and an active community of peers.
Balderton’s Platform continues to expand, and the firm has added 13 people to its team in the last year, including Dave Kellogg, Balderton’s first executive-in-residence. Founding teams also gain access to the global industry leaders of the Balderton Executive Council; the CEO Collective offsite; and events and workshops hosted at the firm’s Kings Cross headquarters and across Europe.
Balderton has also reaffirmed its commitment to building a sustainable and fair venture firm by publishing its Sustainable Future Goals - 60 objectives designed to reduce its impact on the environment, increase its social diversity and improve its governance. Recognising the role that investors play in creating a more sustainable and equal economy, Balderton is sharing its SFGs with portfolio companies and working with them to take action to improve performance against the goals.
Balderton was also proud to be awarded Level 2 Certification of the Diversity VC Standard in 2021, meaning the firm is considered to be leading the way on Diversity and Inclusion policy.
About Balderton Capital:
Balderton Capital is Europe’s leading venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since its founding, Balderton has worked with hundreds of extraordinary European founders, and raised almost $4.5bn across ten funds. Previous exited investments include Betfair (FTSE: BET), Depop (Etsy), Digital Surgery (Medtronic), Frontier Car Group (OLX Group), Flywire (NASDAQ: FLYW), Nutmeg (JPMorgan Chase), Peakon (Workday), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Balderton’s current portfolio includes Aircall, Beauty Pie, Carwow, Citymapper, Contentful, ComplyAdvantage, Darktrace (LSE: DARK), Dream Games, GoCardless, Graphcore, Healx, Infarm, Kobalt Music, Labster, Lyst, Prodigy Finance, Revolut, Sophia Genetics (NASDAQ:SOPH), Tessian, THG (LSE: THG), Truecaller (Stockholm:TRUEB), VanMoof, Vestiaire Collective, Vivino and Zego.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005356/en/
Contact information
Jen Andre
jen@balderton.com
Sayula Kirby
sayula@burlington.cc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 09:00:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This facility was secured prior to IQM’s recent announcement of plans to become the first publicly listed European quantum computing company through a merger with Real Asset Acquisition Corp (“RAAQ”). The facility lowers IQM’s overall cost of capital and improves the flexibility and diversity of its capital base. “The financing package comes at a pivotal time for IQM, as we build momen
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 08:45:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
